leisure time -WSS

leisure time

author：Wikipedia 2025-09-28 21:05:02 - browse：62986

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Congress considering partial increase for doctor pay in Medicare

WSS

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

New company forms to vet health AI models, root out weaknesses

Congress considering partial increase for doctor pay in Medicare

Bernie Sanders gets little from pharma CEOs on drug prices

Pope greeted like rockstar, appears revitalized at 'Catholic Woodstock' in Portugal

Pediatricians' group reaffirms support for gender

focus

leisure time

focus

The cancer drug shortage isn’t new — and neither are the solutions

Medical schools are missing the mark on artificial intelligence

The high cost of giving birth even with insurance

Doctors on social media are being harassed and cyberbullied

Dobbs anniversary: the lost opportunity of abortion as health care

Websites selling Wegovy, Zepbound ingredients targeted by FDA

New air purifier tech could be key to improving indoor air quality

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Virginia high school admissions case could be legal follow

ACIP vaccine advisory panel sees its vacancies filled

leisure time

Pharma needs to include young adults in clinical research

Latigo launches with $135 million for Vertex

Why Eli Lilly’s earnings didn’t quite live up to the hype

Long Covid research funding gets a major boost from NIH

Too many hospitalized Covid

Medical mystery: When an infection after surgery isn’t what it seems

leisure time

entertainment

focus

focus